Status:
TERMINATED
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenic Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psycho...
Eligibility Criteria
Inclusion
- In the opinion of the Investigator, requirement for treatment for an acute episode of schizophrenia, schizoaffective disorder or schizophreniformic psychosis (according to DSM-IV diagnostic criteria), Positive and Negative Symptoms Scale (PANSS) ≥ 65, CGI ≥ 4
Exclusion
- Pregnancy or lactation
- In-patients/hospitalized \> 7 days before enrollment
- Known intolerance or lack of response to quetiapine fumarate or risperidone, as judged by the investigator
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00660595
Start Date
September 1 2008
End Date
December 1 2008
Last Update
September 17 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Harjavalta, Finland
2
Research Site
Helsinki, Finland
3
Research Site
Pitkäniemi, Finland
4
Research Site
Turku, Finland